BioSpace News Archive

Brickell Biotech, Inc. today announced that they have entered into a licensing agreement, whereby Brickell will have the exclusive, worldwide rights to develop and commercialize Carna’s portfolio of novel, potent, and orally available Stimulator of Interferon Genes (STING) antagonists.

M6P Therapeutics, a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal disorders, announced its participation at WORLDSymposium™ 2022 conference on lysosomal disorders and research.

Reneo Pharmaceuticals, Inc. announced that it will be hosting a fireside chat and participating in one-on-one investor meetings at SVB Leerink’s Virtual Global Healthcare Conference taking place February 14-18, 2022.

SomaLogic, a leader in data-driven proteomics technology, announced that the company will begin assaying samples from the Multi-Ethnic Study of Atherosclerosis study beginning in the first quarter of 2022.

VBL Therapeutics announced that Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics, will participate in a fireside chat at the Guggenheim Oncology Conference being held virtually on February 9 – 11, 2022.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, announced that the Company will present at the following upcoming investor conferences.

RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, announced that, as approved and reported after its January 28, 2022 extraordinary general meeting, Michelle Lock, Chief Operating Officer of Covis Pharma Group, has been appointed to the company’s Board of Directors.

The drive for periodontal scalers and curettes market stems from the growing awareness about the problems of plaque and calculus from tooth surfaces and gingival roots.

Next generation hemophilia therapies are aimed at revolutionizing the clinical outcomes and quality of life of hemophilia patients.

Fact.MR – A Market Research and Competitive Intelligence Provider: The vaccine delivery systems market was valued at US$ 3.81 billion in 2021, and is expected to reach US$ 4.14 billion by the end of 2022, reflecting an increase of 8.6% year over year.